2 results
Approved WMORecruiting
To assess the efficacy and safety of LCI699 in CD patients
Approved WMOCompleted
To evaluate the safety and efficacy of subcutaneousbelimumab (GSK1550188) and intravenous rituximab coadministrationin subjects with primary Sjögren*s syndrome.